Increased expression of ALCAMCD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse

British Journal of Cancer

Volumn 101, Issue 3, 2009, Pages 457-464

  Kahlert, C ^a   Weber, H ^a   Mogler, C ^a   Bergmann, F ^a   Schirmacher, P ^a   Kenngott, H G ^a   Matterne, U ^b   Mollberg, N ^a   Rahbari, N N ^a   Hinz, U ^a   Koch, M ^a   Aigner, M ^a   Weitz, J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Institute of Occupational and Social Medicine   (Germany)

Author keywords

ADAM17 TACE; ALCAM; CD166; Pancreatic cancer; Prognostic marker

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CELL ADHESION MOLECULE; CYTOKERATIN 19; FLUOROURACIL; GEMCITABINE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ADAM PROTEIN; ALCAM PROTEIN, HUMAN; FETOPROTEIN; LEUKOCYTE ANTIGEN; NERVE CELL ADHESION MOLECULE; TUMOR MARKER; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CELLULAR DISTRIBUTION; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; GENE DISRUPTION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RELAPSE; CELL ADHESION; CHEMISTRY; MIDDLE AGED; MORTALITY; PANCREAS; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR RECURRENCE;

ADAM PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CELL ADHESION; CELL ADHESION MOLECULES, NEURONAL; FEMALE; FETAL PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 68149132477     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605136     Document Type: Article

References (24)

1. Arribas J, Bech-Serra JJ, Santiago-Josefat B (2006) ADAMs, cell migration and cancer. Cancer Metastasis Rev 25: 57-68
2. Bech-Serra JJ, Santiago-Josefat B, Esselens C, Saftig P, Baselga J, Arribas J, Canals F (2006) Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis. Mol Cell Biol 26: 5086-5095
3. Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, Weichert W, Denkert C, Guski H, Dietel M, Kristiansen G (2006) Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol 59: 403-409
4. Choi S, Kobayashi M, Wang J, Habelhah H, Okada F, Hamada J, Moriuchi T, Totsuka Y, Hosokawa M (2000) Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin. Clin Exp Metastasis 18: 45-50
5. Delcore R, Rodriguez FJ, Forster J, Hermreck AS, Thomas JH (1996) Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am J Surg 172: 463-468; discussion 468-9
6. Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, Schirmacher P, Büchler M (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15: 1651-1660
7. Geer RJ, Brennan MF (1993) Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165: 68-72; discussion 72-3
8. Hellan M, Sun CL, Artinyan A, Mojica-Manosa P, Bhatia S, Ellenhorn JD, Kim J (2008) The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer. Pancreas 37: 19-24
9. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96
10. Jezierska A, Matysiak W, Motyl T (2006) ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit 12: BR263-BR273
11. King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG (2004) Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 6: R478-R487
12. Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, Stephan C, Loening S, Dietel M, Rosenthal A (2005) Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 205: 359-376
13. Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, Petersen I (2003) CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 88: 231-236
14. Lunter PC, van Kilsdonk JW, van Beek H, Cornelissen IM, Bergers M, Willems PH, van Muijen GN, Swart GW (2005) Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 65: 8801-8808
15. Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, Pilotti S, Canevari S (2008) Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 14: 1726-1733
16. Mochizuki S, Okada Y (2007) ADAMs in cancer cell proliferation and progression. Cancer Sci 98: 621-628
17. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervernis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW (2001) Adjuvant chemotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 10: 1576-1585
18. Ringel J, Jesnowski R, Moniaux N, Luttges J, Choudhury A, Batra SK, Kloppel G, Lohr M (2006) Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res 66: 9045-9053
19. Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, Canevari S, Orengo AM, Puppo A, Ferrini S, Fabbi M (2007) The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 5: 1246-1253
20. Swart GW (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 81: 313-321
21. Tomita K, van Bokhoven A, Jansen F, Kiememey L, Karthaus H, Vriesema J, Bussemakers M, Witjes JA, Schalken JA (2003) Activated leukocyte cell adhesion molecule (ALCAM) expression is associated with a poor prognosis for bladder cancer patients. UroOncology 3: 121-129
22. van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP, Swart GW (2000) Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 156: 769-774
23. Verma A, Shukla NK, Deo SV, Gupta SD, Ralhan R (2005) MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology 68: 462-470
24. Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G (2004) ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 57: 1160-1164